| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/31/2008 | WO2008014286A1 Vinyl phosphonate lysophosphatidic acid receptor antagonists |
| 01/31/2008 | WO2008014236A1 Dimeric iap inhibitors |
| 01/31/2008 | WO2008014060A2 Microparticle |
| 01/31/2008 | WO2008013791A2 Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
| 01/31/2008 | WO2008013631A2 Composition for the enterosorption and management of toxins comprising a calcium aluminosilcilate clay |
| 01/31/2008 | WO2008013324A1 Use of diabetes-related, liver-derived secreted protein in diagnosis or treatment of type-2 diabetes or vascular disorder |
| 01/31/2008 | WO2008013276A1 Therapeutic agent for malignant mesothelioma |
| 01/31/2008 | WO2008013082A1 Galectin 9-polymer conjugate |
| 01/31/2008 | WO2008012945A1 3'-ethynylcytidine derivative |
| 01/31/2008 | WO2008012534A2 Retinoids and small molecules as nrf2 antagonists for use in the treatment of diseases associated with abnormal cell proliferation |
| 01/31/2008 | WO2008012326A1 2,4-substituted quinazolines as lipid kinase inhibitors |
| 01/31/2008 | WO2008012105A1 Crystalline erlotinib |
| 01/31/2008 | WO2008012003A1 Camptothecin derivatives with antitumor activity |
| 01/31/2008 | WO2008011994A1 Camptothecin derivatives with antitumor activity |
| 01/31/2008 | WO2008011992A1 Camptothecin derivatives with antitumor activity |
| 01/31/2008 | WO2008011805A1 Vinblastines compounds, the preparation and the pharmaceutical use thereof |
| 01/31/2008 | WO2008011799A1 NEW USE OF NON-RECEPTOR TYROSINE KINASE c-Ab1 SPECIFIC INHIBITORS |
| 01/31/2008 | WO2008011752A2 Drugs for resisting bacteria, viruses, cancers, tumors, irritabilities and defects |
| 01/31/2008 | WO2008011726A1 Staged immune-response modulation in oncolytic therapy |
| 01/31/2008 | WO2008011711A1 Cancerous disease modifying antibodies |
| 01/31/2008 | WO2008011710A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 01/31/2008 | WO2007149395A3 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer |
| 01/31/2008 | WO2007140297A3 Aziridinyl-epothilone compounds |
| 01/31/2008 | WO2007075808A3 Methods for preventing and/or treating a cell proliferative disorder |
| 01/31/2008 | WO2007052267A3 Biodegradable composite for internal local radiotherapy |
| 01/31/2008 | WO2006110814A3 Methods for treating diseases through inhibition the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
| 01/31/2008 | WO2006094917A8 Oligodeoxyribonucleotides of 4000-10000 dalton for treating tumors |
| 01/31/2008 | US20080027224 silyl camptothecin derivatives for cancer and/or leukemia; cytotoxic; DNA-topoisomerase I inhibitors; antitumor agents; 7-trimethylsilyl-10-acetoxy camptothecin, 7-trimethylsilyl-11-fluoro camptothecin |
| 01/31/2008 | US20080027214 Modulation of immunostimulatory activity of immunostimulatory Oligonucleotide analogs by positional chemical changes |
| 01/31/2008 | US20080027148 Drug targets related to synthase subfamily; alternative splice forms; isolated peptides and antibodies |
| 01/31/2008 | US20080027145 Therapeutic Molecules and Methods for Generating and/or Selecting Same |
| 01/31/2008 | US20080027135 Methods For Identifying Chemical Modulators Of Ras Superfamily Gptase Activity |
| 01/31/2008 | US20080027133 Use of chromen-4-one derivatives |
| 01/31/2008 | US20080027130 Cytotoxic agents comprising taxanes and their therapeutic use |
| 01/31/2008 | US20080027123 Reduction of levels of tumor necrosis factor-alpha and/or inhibition of phosphodiesterase 4; treating erythema nodosum leprosum in leprosy, rhematoid spondylitis, hepatitis or congestive heart failure |
| 01/31/2008 | US20080027121 Novel pyrone-indole derivatives and process for their preparation |
| 01/31/2008 | US20080027118 Prodrugs Of Mitotic Kinesin Inhibitors |
| 01/31/2008 | US20080027110 Indolyl-3-glyoxylic acid derivatives having antitumor action |
| 01/31/2008 | US20080027107 With nitrogen containing heterocyclic substituents; for example, 1-{[(2-dimethylamino)ethyl]amino}-4-{[2-(3-hydroxypiperidin-1-yl)ethyl]amino}-anthracene-9,10-dione |
| 01/31/2008 | US20080027102 Quinolinyl-pyrrolopyrazoles |
| 01/31/2008 | US20080027086 Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
| 01/31/2008 | US20080027084 antiinflammatory agent, anticarcinogenic agent; for treating inflammatory diseases, allergic, autoimmune, metabolic, cancer, cardiovascular diseases |
| 01/31/2008 | US20080027083 Modulators of chemokine receptor activity crystalline forms and process |
| 01/31/2008 | US20080027080 Cyclic derivatives as modulators of chemokine receptor activity |
| 01/31/2008 | US20080027078 9-[2-(1H-indol-3-yl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one; glycogen synthase kinase 3 beta inhibitors; nerve growth factors; neurodegenerative diseases; Alzheimer's disease; Parkinson's disease; tauopathies; stroke; vision defects;antidiabetic agent; anticarcinogenic |
| 01/31/2008 | US20080027070 2-amino--5-substituted pyrimidine inhibitors |
| 01/31/2008 | US20080027069 Quinazoline compounds |
| 01/31/2008 | US20080027068 Heterocyclic compounds and thrombopoietin receptor activators |
| 01/31/2008 | US20080027063 Imidazopyrazines as protein kinase inhibitors |
| 01/31/2008 | US20080027058 Mitotic Kinesin Inhibitors |
| 01/31/2008 | US20080027054 4-Substituted quinolines as antitumor agents |
| 01/31/2008 | US20080027045 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents |
| 01/31/2008 | US20080027036 S1P receptor modulating compounds and use thereof |
| 01/31/2008 | US20080027023 Antiproliferative Compositions Comprising Aryl Substituted Xylopyranoside Derivatives |
| 01/31/2008 | US20080027010 Treatment of refractory cancers using Na+/K+-ATPase inhibitors |
| 01/31/2008 | US20080027008 Antitumorigenic Drug Combination |
| 01/31/2008 | US20080027004 Phosphorylated COP1 molecules and uses thereof |
| 01/31/2008 | US20080026998 Human kunitz-type inhibitor with enhanced antifibrinolytic activity |
| 01/31/2008 | US20080026986 Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling |
| 01/31/2008 | US20080026985 Control of gene expression |
| 01/31/2008 | US20080026444 Process For Producing Protein-Polymer Complex |
| 01/31/2008 | US20080026402 Hematopoietin receptors HPR1 and HPR2 |
| 01/31/2008 | US20080026088 Reduced isoalpha acid based protein kinase modulation cancer treatment |
| 01/31/2008 | US20080026070 Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications |
| 01/31/2008 | US20080026048 Reovirus for the treatment of cellular proliferative disorders |
| 01/31/2008 | US20080026047 Cancer Detection Reagents And Uses In Pathology And Diagnostics And Cancer Cell Death |
| 01/31/2008 | US20080026046 Stable Aqueous G-Csf Conatining Compositions |
| 01/31/2008 | US20080026045 Combination Chemotherapy Comprising a Gemcitabine and a Liposomal Platium Complex |
| 01/31/2008 | US20080026044 Combination Chemotherapy Comprising Capecitabine and a Liposomal Platinum Complex |
| 01/31/2008 | US20080026012 Recombinant cancer cell secreting modified heat shock protein-antigenic peptide complex |
| 01/31/2008 | US20080026011 Immunostimulatory nucleic acid molecules |
| 01/31/2008 | US20080026001 Pharmaceutical composition from natural materials for regulating immunity, its preparation method and use |
| 01/31/2008 | US20080025990 anti-IGFR1 antibodies; combination with topoisomerase inhibitor such as irinotecanp; antitumor |
| 01/31/2008 | US20080025984 Combination Therapy Comprising Cloretazine |
| 01/31/2008 | US20080025983 Methods of screening based on the EGF receptor crystal structure |
| 01/31/2008 | US20080025981 Cancer-linked genes as targets for chemotherapy |
| 01/31/2008 | US20080025979 Programmed Death 1(PD-1); bispecific antibodies comprising antibodies against human T cell receptor complex or human B cell receptor complex; autoimmune diseases |
| 01/31/2008 | US20080025972 Treating sex steriod responsive disorders |
| 01/31/2008 | US20080025964 Modified ribonucleases |
| 01/31/2008 | US20080025946 Interleukin 21 and tyrosine kinase inhibitor combination therapy |
| 01/31/2008 | US20080025944 Combination Therapy for Immunostimulation |
| 01/31/2008 | US20080025921 Conductance of Improperly Folded Proteins Through the Secretory Pathway And Related Methods For Treating Disease |
| 01/31/2008 | US20080025919 Benzoylguanidine salt and hydrates thereof |
| 01/31/2008 | US20080025916 Tailored Treatment Suitable for Different Forms of Mastocytosis |
| 01/31/2008 | US20080025913 Novel Anti-Dc-Sign Antibodies |
| 01/31/2008 | DE102006035083A1 Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel Protein-binding methotrexate derivatives and pharmaceutical compositions containing them |
| 01/31/2008 | DE102006034256A1 Verbesserung der Bioverfügbarkeit von Wirkstoffen mit Amidinfunktion in Arzneimitteln Improve the bioavailability of drugs with amidine in drugs |
| 01/31/2008 | CA2666515A1 Cancerous disease modifying antibodies |
| 01/31/2008 | CA2666464A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 01/31/2008 | CA2659353A1 Composition and method for treatment of tumors |
| 01/31/2008 | CA2659307A1 Crystalline erlotinib |
| 01/31/2008 | CA2659050A1 Camptothecin derivatives with antitumor activity |
| 01/31/2008 | CA2658917A1 3'-ethynylcytidine derivative |
| 01/31/2008 | CA2658902A1 Camptothecin derivatives with antitumor activity |
| 01/31/2008 | CA2658900A1 Camptothecin derivatives with antitumor activity |
| 01/31/2008 | CA2658782A1 Compounds and compositions as hedgehog pathway modulators |
| 01/31/2008 | CA2658624A1 Pyridazine and pyrrole compounds, processes for obtaining them and applications thereof |
| 01/31/2008 | CA2658587A1 Drug delivery system based on regioselectively amidated hyaluronic acid |
| 01/31/2008 | CA2658584A1 Staged immune-response modulation in oncolytic therapy |
| 01/31/2008 | CA2658436A1 A novel lactic acid formulation of mk-0457 useful for the treatment of cancer |